Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00512876 · ClinicalTrials.gov registry record · NA
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
A NA study, sponsored by Walter Reed Army Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT00512876 is a NA study that has completed, run by Walter Reed Army Medical Center. The registered enrollment target is 24 participants.
The verdict
NCT00512876, a NA study, has completed, sponsored by Walter Reed Army Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.
Interventions
- DRUG Bevacizumab (Avastin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00512876
The ClinicalTrials.gov registry entry for NCT00512876 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Walter Reed Army Medical Center, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab (Avastin) is the first listed.
NCT00512876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00512876 about?
NCT00512876 is a clinical study titled "Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization". Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.
What is the current status of trial NCT00512876?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2007-08. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00512876?
The interventions under investigation include: Bevacizumab (Avastin) (DRUG).
Who is sponsoring clinical trial NCT00512876?
This trial is sponsored by Walter Reed Army Medical Center, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.